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Background: Levothyroxine (LT4) treatment can lead to iatrogenic hyperthyroidism and oxidative stress that can
cause patient discomfort. Oxidative stress is also recognized as one of the causes of chronic diseases and cancer.
Methods: The prevalence of breast, colorectal, gastric and lung cancer in 18 Italian Regions during 2010 was
correlated with the sales of LT4 in 2009. The cancer prevalence was analyzed in women aged 30–84. This age range
corresponds to more than 80% of the consumers of the drug and to about 99% of all malignant cancers. The
correlation between sales of LT4 and cancers was determined with the technique of Density Ellipses. The age and
smoking contribution for lung cancer was determined with the Sequential test.
Results: No significant correlation was seen between LT4 sales and breast, colorectal and gastric cancers. A
significant correlation was instead found for lung cancer (p < 0.05) corrected for smoking and age.
Conclusions: LT4 consumption in Italy is about 0.7 boxes/women/year. There is a correlation between lung cancer
and LT4 treatment and oxidative stress caused by LT4 supplementation can be one of the causes. Although we
cannot exclude that dysthyroidism needing LT4 supplementation might be the ground for lung cancer itself and
measuring oxidative stress could be helpful in avoiding excessive use of the drug.
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During studies aimed at assessing the relationship between
food intake and metabolic syndrome in Italy, a large
number of subjects was found to use levothyroxine
(LT4) for hypothyroidism.
A survey conducted in USA on the intake of thyroid
supplements [1] found that side effects may occur in as
many as 20% of treated cases, the most common being
palpitation, sweating, agitation/anxiety and daily dis-
comfort which are typical symptoms of iatrogenic hy-
perthyroidism.
A clinical study indicated that these side effects were
correlated with the increase of plasma hydroperoxides
which are markers of oxidative stress [2], and the use
of a pool of physiological modulators (PMs) with anti-
oxidant activity was found effective in reducing all
these side effects [3].* Correspondence: finco.annarosa@libero.it
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reproduction in any medium, provided the orThese findings suggest that the chronic use of LT4 is
consistent with an overproduction of reactive oxygen
species (ROS) caused by the hypermetabolic status pro-
voked by administration of this hormone [4-6].
Achievement of euthyroid status is monitored by
measuring TSH, T3 and T4 plasma levels, mainly in the
morning on a empty stomach, a few times in a year, but
measuring oxidative stress was never considered a useful
tool for adjusting LT4 doses. The LT4 administration
leads to T4 and T3 peak between one and two hours
after the drug is taken [7,8]. These peaks triggers an
increase of plasma hydroperoxides which is reduced
by the administration of physiological modulators with
antioxidant activity [2,3].
The aim of the present research was to correlate the
LT4 as a chronic oxidative stress generator with the
prevalence of four different types of tumors: breast, colo-
rectal, gastric and lung in 18 Italian Regions. Since more
than 80% of supplement prescriptions of the supplement
are made out to women, the correlation between LT4
sales and cancers was calculated for females only.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Cornelli et al. Reproductive Biology and Endocrinology 2013, 11:75 Page 2 of 6
http://www.rbej.com/content/11/1/75Methods
Data on LT4 sales, sales in pharmacy in 18 Italian regions
in 2009 and 2010, were provided by IMS (Intercontinental
Marketing Service). These data were correlated with the
prevalence of breast, colorectal, gastric and lung cancers
in females in the same regions.
The IMS sex distribution and age group data show
that 83.5% of the LT4 prescriptions were made out to
females, and 94.4% were to patients aged more than
30 years. Public data on cancer incidence, prevalence
and mortality in Italy can be obtained on line and are
reported by type of cancer, sex/age/Region (www.tumori.
net). The raw prevalence data (number of cases/100,000
inhabitants) in the of 30–84 years age group was taken
and correlated with the drug sales, regardless of the
different doses used.
Smoking prevalence was obtained by Istat.it (www.
istat.it) from and the relative sex distribution from
OSSFAD (Osservatorio Fumo Alcol e Droga Istituto
Superiore di Sanità- report May 31, 2010). The average
prevalence between 2007 to 2009 in the 18 Italian
Regions was taken for the evaluation because data
before 2007 were not available for all Regions. Aging
index was taken by Istat.it.Statistical methods
The continuous variables “prevalence” and “sales LT4”
were analyzed by correlation analysis with the technique
of Density Ellipse [9]. The correlations analysis yields
only one number, an index designed to give an immedi-
ate picture of how closely two variables move together,
while the ellipse represents all combinations of X and Y
with the same probability density. It is called an iso-
probability curve. The straight line represents the axis
common to all these level curves. If the bivariate normal
distribution concentrates about this major axis, ρ has a
higher numerical value. These ellipses are both density
contours and confidence curves. As confidence curves,
they show where a given percentage of the data is ex-
pected to lie, assuming the bivariate normal distribution.
The densities of the ellipse were drawn with p = 0.90.
In case of correlation between LT4 and cancer the
Multiple Regression Analysis was applied followed by
the Sequential test (or type ISS) to highlight the contribu-
tion of single variables (aging, smoke and LT4 treatment).
The statistical analysis applied to data is a multiple
regression model with the stepwise specification. The
Stepwise feature computes estimates that are the same as
those of other least squares platforms, but it facilitates
searching and selecting among many models. Sequential
Tests show the reduction in residual sum of squares as
each effect is entered into the fit. The sequential tests are
also called Type I sums of squares (Type I SS). A desirableproperty of the Type I SS is that they are independent and
sum to the regression SS.
Results
The Italian females population aged between 30 and
84 years was estimated to be about 19.89 million in 2010
(http://dati.istat.it/) and the relevant sales of LT4 in 2009
amounts to 13.93 million boxes (total sales 16.68 million
boxes without considering the different dosages) corre-
sponding to a yearly consumption of 0.7 boxes/woman.
The data concerning the different cancers, smoking and
aging index are reported in Table 1.
The correlation between smoking and the four cancers
(data not reported) was statistically significant for lung
cancer only (p < 0.05) while for all the other type of can-
cer was practically inconsistent.
The aging index was shown to be significant for colo-
rectal cancer only (p < 0.05) and not for all the other
type of cancer (data not reported).
For what concern the correlation between sales of LT4
and cancers the data are reported in Figure 1 (A,B,C,D).
The prevalence sales ellipsis is relatively wide, which
corresponds to no significant correlation.
The data concerning colorectal cancer and LT4 sales
(Figure 1B) show that, for this type of tumor, there was
no significant relationship and, like in the case of breast
cancer, data were spread out over a large ellipsis.
The values of the relationship between sales and pre-
valence are also distributed over a wide area in the case
of stomach cancer (Figure 1C).
A significant (p < 0.05) correlation was found for lung
cancer (Figure 1D).
Smoking is known to be related to lung cancer and to
cause an over-fitting effect that hides the possible con-
tribution of other variables such as aging and LT4. The
sequential analysis applied to the data eliminated the
effect of smoking and made evident the contribution of
aging and LT4.
The results were that age do not contribute signifi-
cantly to the development of lung cancer (p = 0.532)
whereas LT4 is significantly related to lung cancer (p =
0.003).
A more evident differentiation can be drawn splitting
smoking prevalence into three different age range 25–
44, 45–64, and 65–84 that was respectively 24.3, 25.9
and 7.4 (OSSFAD 2010 report May 31, 2010). This
means that the smoking prevalence was reduced by
three times in the last age range. The prevalence of LT4
use instead was respectively 18.6, 35.1 and 35.2, showing
that in the two age ranges the drug consumption was
identical whereas the lung cancer prevalence was re-
spectively 8.1, 64.3 and 199.2. In other words, in the last
range, to a drastic reduction of smoking (−71%) was cor-
responding a sharp increase of lung cancer (+300%).
Table 1 Levothyroxine sales (number of boxes sold), raw prevalence of some cancer in females in 18 different Italian
regions in 2010 in relation to the sales of LT4 in 2009; average smoking prevalence in women between 2007 and 2009
Type of cancer and prevalence (105) in females
Areaa Sales LT4
b Breast Colorectal Gastric Lung Smokingc Aging indexd
1 1072879 3165.62 776.88 120.04 97.47 21.6 139.9
2 1028179 3118.67 646.35 96.03 68.08 23.0 150.0
3 267126 2669.96 714.53 199.34 100.45 26.5 180.5
4 273291 3210.26 750.28 131.17 72.57 20.0 116.5
5 1438397 1589.44 370.62 76.35 82.94 23.0 120.2
6 1179775 2674.95 625.72 182.42 91.74 26.0 184.1
7 487525 2250.40 416.66 55.21 62.85 20.0 154.8
8 1087091 1418.33 374.09 87.74 60.79 22.0 122.1
9 405995 1579.13 389.64 103.25 54.03 21.0 168,9
10 408040 2722.42 716.09 198.61 84.07 23.0 168.7
11 1879231 2909.03 733.82 174.65 77.41 29.0 141.9
12 467753 2824.49 751.36 90.85 82.19 23.0 234.6
13 2423825 2882.24 557.33 109.31 138.66 29.0 141.6
14 287660 3424.94 837.82 162.56 116.44 23.1 187.4
15 1474482 3269.15 815.26 169.85 94.09 26.0 170.0
16 631585 1442.77 329.72 97.17 44.45 22.8 130.2
17 1682805 1622.33 378.19 99.62 96.59 27.0 96.5
18 183079 1474.73 430.39 100.85 45.98 16.0 148.2
a1-Veneto; 2-Piemonte-Valle d’Aosta; 3-Umbria; 4-Trentino Alto Adige; 5-Sicilia; 6-Toscana; 7-Sardegna; 8-Puglia; 9-Abruzzo-Molise; 10-Marche; 11-Lombardia;
12-Liguria; 13-Lazio; 14-Friuli Venezia Giulia; 15-Emilia Romagna; 16-Calabria; 17-Campania; 18-Basilicata;
bSales of LT4, boxes regardless to different doses in 2009, data from IMSHealth–ITSSMS–Anno 2009;
caverage smoking prevalence from 2007 and 2009 (× 100 people);
dAging index in 2010.
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of cancers in 2010 (instead of sales in 2009-data not
reported), and the values were almost identical.
Discussion
The findings of this research suffer of many limitations
due to type of data that analyzed.
For instance, the impossibility to determine the LT4
dosage does not allow dose/effect relationship to be
looked into. In addition, the lack of sex distribution of
the drug in the different regions, the nonexistence of a
study protocol and a clinical record form to guide the
study may limit further the data interpretation. However,
13.9 million boxes spread between 14 million women are
very sizeable figures and may give important indications.
In this assessment no relationship was found between
LT4 prescription and breast cancer among the Italian
population.
The average prevalence measured in the regions of
Southern of Italy (Sicilia, Puglia, Abruzzo/Molise, Calabria,
Campania, Basilicata, Sardegna) was 1600.65 compared
to value of 2998.59 in all the other regions. This difference
could be due to Mediterranean diet, which is more wide-
spread in Southern Italy and improves the AO capacity.The relationship between oxidative stress and this type
of cancer was examined in the Long Island Breast Can-
cer Study Project through the measurement of urinary
isoprostane (15-isoprostane F2t) which mirrors oxidative
stress due to lipid peroxidation [10]. A positive correl-
ation was found between urinary isoprostrane levels
and cancer, which underlines the importance of oxida-
tive stress measurement.
It may be possible that the AO intake in the Southern
regions of Italy have diluted the pro-oxidant effect of
LT4 in all the country and made inconsistent the cor-
relation between the two variables under study.
No correlation was found in our study between colorec-
tal cancer and LT4 administration. A negative correlation
with long term use of LT4 (< 5 years) was described in
literature in a case–control study on colorectal cancer
conducted in Northern Israel [11]; in the case of women,
the effect was independent from the use hormone re-
placement therapy (HRT).
The prevalence of colorectal cancer in the regions of the
Southern Italy was lower than in all the other Italy (376.43
and 704.92 respectively), and seems again to be consistent
with the fact that the Mediterranean diet is more common
in the South of Italy than in the other Italian regions.
Figure 1 Levothyroxine sales (number of boxes sold). A) Raw breast cancer prevalence (105) in female in 18 different Italian Regions. Each
point corresponds to a region. B) Raw colorectal cancer prevalence (105) in female in 18 different Italian regions. Each point corresponds to a
region. C) Raw gastric cancer prevalence (105) in female in 18 different Italian regions. Each point corresponds to a region. D) Raw lung cancer
prevalence (105) in female in 18 different Italian regions. Each point corresponds to a region.
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LT4 and gastric cancer. In this case also the regions of
Southern of Italy showed a much lower prevalence than
all the other Regions (86.30 and 154.93 respectively),
suggesting that the Mediterranean diet might be consid-
ered a protective tool against this cancer too.
In the Seven Country Study [12] a relationship was
found between diet and stomach cancer in two Italian
rural population groups. Unfortunately the study was
aimed at man only, though the increase in death for
gastric cancer was significantly related to high polyun-
saturated fatty acid (PUFA) intake that increase oxida-
tive stress [13].
Lung cancer was the only tumor found directly cor-
related with LT4 supplementation. The prevalence inSouthern Italy and the rest of the country were 73.53
and 92.89 respectively, with a far lower difference than
for the other three cancers.
The importance of smoking, aging and LT4 were consid-
ered in the multivariate analysis followed by the Sequential
test and showed that smoking and LT4 were much more
responsible for lung cancer than aging. When smoking
prevalence was eliminated by the evaluation still the
relationship between LT4 and lung cancer remained
significant; when similar evaluation was conducted with
other type of cancer, the correlation was not significant
(data not reported).
We may not exclude that the condition of hypo-
thyroidism could favor the development of lung cancer.
On the opposite it has been described recently that
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cers because of the presence of thyroid hormone receptors
on cancer cells, and spontaneous hypothyroidism may
delay onset or reduce aggressiveness of cancers [14].
Recently LT4 has been reported as one of the several
endogenous factors capable of supporting proliferation
of lung cancer cells [15]. The observation that patients
with small cell carcinoma of the lung often present
symptoms suggestive of hyperthyroidism (i.e. weight loss,
anorexia) was made many years ago together with an
over production of both T4 and T3 [16]. An old clinical
observation on the relationship between lung cancer
and thyroid function [17] reported that patients were
characterized by a low concentration of T3 and an in-
creased T4/T3 ratio due to a decrease of 5’-monode-
iodination (DI). More recently DI activity in lung cancer
was found to be lower than in peripheral lung tissue [18].
In experimental animals has been already shown that
LT4 increases the oxidative stress [19] and spontaneous
pulmonary metastases in mice [20]. Furthermore, in rats
lung the deiodination of LT4 is the lowest compared to
all the other tissues [21]. This means that the amount
of LT4 reaching the lungs following an external supple-
mentation cannot to be transformed into LT3 as in the
other tissues, and make lungs very vulnerable to possible
toxic effects of LT4.
During the therapy with LT4 even at the steady state
condition a peak of the hormone is evident a couple of
hours after the administration and may cause a temporary
condition of hyperthyroidism and a further increase of
oxidative stress.
Oxidative stress is well documented in hypothyroidism
[22-24] and is even worsened through treatment with
LT4 [1,2]. The difference between the two conditions is
that, in case of hypothyroidisms, oxidative stress is due
to the reduction of AO [4], whereas, after the LT4 treat-
ment it stems from overproduction of ROS from mito-
chondria [5,6].
A very simple method that can be used to measure
oxidative stress is related to hydroperoxides content in
plasma which is considered a very reliable test compared
to other common methods since it shows very limited
coefficient of variation [25].
An inverse association with fruit and vegetables con-
sumption and lung cancer recently has been docu-
mented recently in the EPIC study for 50 to 59 age
group, without an effect on specific histological sub-
types [26].
These data support the importance of the oxidative
stress control in lung cancer, as was documented by the
increase in urinary isoprostanes in subjects at risk of
cancer in the Multiethnic Cohort Study [27].
LT4 can alter the oxidative balance in lungs and behave
as a negative factor because of oxidative stress, and thecondition of oxidative stress should be controlled as a
routine measurement.
There should be a reason why oxidative stress taking
place during the treatment with LT4 seems particularly
related to lung cancer only. The hypothesis could be that
in lungs the increase of hypoxia-induced factor (HIF-1)
which is determined by T4 can make oxygen much more
available, increasing locally the oxidative stress together
with a dangerous angiogenesis stimulation [28-30].
Although we should never forget that LT4 is a life-saving
thyroid hormone replacement, and that one should not
exclude that the pathological reason that leads to the
prescription of LT4 could favor the lung cancer devel-
opment also.
However, the impression we get from our experience
in epidemiological studies monitoring [31] is that this
drug should be prescribed more cautiously. Considering
that the population in Italy is about 60 million people
and the sales of LT4 in the country in 2010 were 17.69
million boxes (+ 6% Vs 2009), hypothyroidism, which is
the main reason for the prescription, should be a real
national concern (almost 0.7 boxes/women/year).
Most of the time, doctors tell patients treated with
LT4 that any side effects will be temporary and almost
ineluctable, and are usually dealt with through dose
reduction. Assessment of oxidative stress and its balance
has not been taken into consideration up to now as it
should be.
Furthermore in case of oxidative stress and side effects
could be important to use different type of thyroid sup-
plementation, such as: liothyronine as well as Armour
Thyroid and control the hydroperoxides levels to deter-
mine if these compounds are safer than levothyroxine.
A last comment should be made regarding the data
stemming from drug sales, which are commonly used to
check sales force performance and decide on marketing
and sales development strategies. These data can provide
extremely helpful information about the risk/benefit ratio
of any drug therapy.
Conclusions
Despite the common knowledge that LT4 is a life-saving
drug, some concern has to be addressed for its pre-
scription. The findings based on the sales of LT4 in
Italy are consistent with the hypothesis that there is a
direct correlation between this drug and lung cancer,
whereas there is no correlation with breast, colorectal
and gastric cancer. However, the clinical background of
hypothyroidism, which is the main reason for prescribing
the drug, might also be involved in the development of
lung cancer. Specific epidemiological studies should be
conducted to test these two hypothesis.
This work is focused on Italian population, so it should
be interesting to conduct similar studies in other regions
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and subjected to different diets in order to verify if this
correlation exist.
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